NuGen Medical Devices (TSXV:NGMD) Announces Partnership with Unifire Inc. to Distribute its Needle-Free Injection Device to US Government Agencies
- NuGen M.D has signed a master distribution and marketing agreement with Unifire Inc. to distribute its InsuJet™ needle-free injection device.
- The agreement gives Unifire the exclusive right to sell its needle-free injection device in the United States as well as non-exclusive rights in Israel and Australia
- Unifire will act as NuGen M.D.’s master distributor to various United States government agencies
- Shares in NuGen M.D. (NGMD) are currently up 31.82% on the TSXV, trading at CA$0.29 per share
NuGen M.D. has signed a master distribution and marketing agreement with Unifire Inc. for its InsuJet™ needle-free injection device.
Unifire is a wholly-owned subsidiary of Mission Ready Solutions (TSXV:MRS, OTCQX:MSNVF) that specializes in providing mission-critical equipment for military, fire rescue, and law enforcement worldwide.
The agreement grants Unifire the exclusive right to sell its needle-free injection device in the United States as well as non-exclusive rights in Israel and Australia.
“Unifire will support NuGen in carrying out its expansion strategy in the US market by focusing on gaining acceptance for InsuJet™ as a safe, reliable and cost-effective replacement solution for current medication injection standards within Unifire’s well-established clientele of government agencies,” said NuGen M.D. CEO Michael Wright.
NuGen M.D.’s needle-free injection system is the first ever self-administered needle-free injection system approved by Health Canada and gives access to safe, cost-effective drug delivery for the millions of patients who suffer from diabetes or other chronic illnesses.
Unifire will act as NuGen M.D.’s master distributor to various United States government agencies, including the Department of Defense (DoD), Biomedical Advanced Research and Development Authority (BARDA), Defense Advanced Research Projects Agency (DARPA), Veterans Affairs (VA), Department of Homeland Security (DHS) and Health and Human Services (HHS).
“We are very pleased to be onboarding this revolutionary solution for medical injections,” said Unifire COO Dan Raczykowski. “Through our initial conversations with our established clientele and government advisors here and abroad, there is an urgent need for safer and more cost-effective solutions to deliver medicine that require injections.”
Mr. Douglas Bryce, Former Joint Program Executive Officer for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) for the US Army and responsible for the development acquisition, distribution, and deployment of highly specialized and dynamic joint CBRN defense devices, medical diagnostics systems, drugs, and vaccines confirms: “The disruptive nature of the needle-free injection solution to improve the standard of care for members and the general public cannot be understated. The safe, rapid, and effective delivery of medication through this device are within the mandates of the government to improve care, reduce waste and lower costs.”
Unifire will work collaboratively with NuGen M.D. to seek regulatory approval, garner political support, introduce non-dilutive government funding, while advising on the necessary manufacturing and supply chain requirements to be eligible to submit to government RFPs.
NuGen Medical Devices is an emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies.
Shares in NuGen M.D. (NGMD) are currently up 31.82% on the TSXV, trading at CA$0.29 per share as of 3:38 pm EST.
About the Kinvestor Network
The Kinvestor Network is an exclusive network of investors that want access to enhanced research and reporting. Members of the Kinvestor Network have access to exclusive articles, reports, models and various other tools that investors may find useful.
Visit the Kinvestor Network for more free content, including in-depth research reports, industry documentaries, CEO interviews, and more.
Please read this disclaimer in its entirety before reviewing any opinions, views or information expressed by Kin Communications Inc. (“Kin”).